A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Czechia- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to Czechia76 clinical trials in Zlin, Czechia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in CzechiaKlinickeTesty.cz(opens in a new tab)
Czechia
Czechia
Czechia
Czechia
Czechia
Czechia
Czechia
Czechia
Czechia
Czechia
Czechia
CzechiaThe busiest research cities in the country
What the registry says about research in the country
Extensive research focusing on psoriatic arthritis treatments, including multiple trials evaluating novel therapies like zasocitinib, sonelokimab, and bimekizumab for patients with varying treatment histories. Additional studies explore treatments for polymyalgia rheumatica and rheumatoid arthritis.
Innovative trials addressing atherosclerotic cardiovascular disease and stroke prevention. Studies evaluate new treatments like pelacarsen for lipoprotein management and asundexian for stroke prevention in patients with atrial fibrillation.
Research initiatives examining treatments for multiple sclerosis, including studies of frexalimab and tolebrutinib. Additional focus on neurosurgical interventions and their postoperative outcomes.
Tell us about your condition – we search every trial in Europe and connect you with the right site.